Probe of poor manufacturing practices now extends beyond ARBs
The FDA continues to recall angiotensin II receptor blocker (ARB) medications for nitrosamine contamination but, in a statement issued Wednesday morning, offered assurance that it is tackling the manufacturing practices underlying the problem.